- Record: found
- Abstract: not found
- Article: not found
Final results of a randomized phase 2 study showing the clinical benefit of quizartinib (AC220) in patients with FLT3-ITD positive relapsed or refractory acute myeloid leukemia
G.J. SCHILLER, M.S. Tallman, S.L. Goldberg, A.E. Perl, J.-P. Marie, G. MARTINELLI, R.A. LARSON, N. RUSSELL, D Trone, G Gammon, GJ Schiller, MS Tallman, SL Goldberg, AE Perl, JP Marie, RA Larson, MJ Levis, JE Cortes, G Martinelli, N Russell
2014
Read this article at
ScienceOpenPublisher
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.